Diagnostic Center | October 27, 2022
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Results reinforce commitment to next-generation oral SERD development programme
Results reinforce commitment to next-generation oral SERD development programme
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.
Study achieves primary endpoint of radiographic progression-free survival
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Construction is now underway with the facility scheduled to be operational by 2025
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Funds raised will be used to develop technology and foster healthcare partnerships
Subscribe To Our Newsletter & Stay Updated
